Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Cash & Equivalents (2016 - 2026)

Aytu Biopharma has reported Cash & Equivalents over the past 15 years, most recently at $30.0 million for Q4 2025.

  • Quarterly Cash & Equivalents rose 47.2% to $30.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $30.0 million through Dec 2025, up 47.2% year-over-year, with the annual reading at $31.0 million for FY2025, 54.71% up from the prior year.
  • Cash & Equivalents was $30.0 million for Q4 2025 at Aytu Biopharma, down from $32.6 million in the prior quarter.
  • Over five years, Cash & Equivalents peaked at $49.9 million in Q2 2021 and troughed at $18.2 million in Q1 2025.
  • The 5-year median for Cash & Equivalents is $20.4 million (2024), against an average of $25.8 million.
  • Year-over-year, Cash & Equivalents crashed 61.2% in 2022 and then skyrocketed 62.27% in 2025.
  • A 5-year view of Cash & Equivalents shows it stood at $35.3 million in 2021, then plummeted by 44.72% to $19.5 million in 2022, then increased by 0.14% to $19.5 million in 2023, then increased by 4.45% to $20.4 million in 2024, then soared by 47.2% to $30.0 million in 2025.
  • Per Business Quant, the three most recent readings for AYTU's Cash & Equivalents are $30.0 million (Q4 2025), $32.6 million (Q3 2025), and $31.0 million (Q2 2025).